| 2017 | 2018 | 2019 | 2020 (projected) | Consolidated Income | 21.36 B | 11.19 B | 16.3 B | 15.73 B | Direct Expenses | 11.24 B | 11.25 B | 10.22 B | 12.13 B |
Is Pfizer Inc Undervalued?
 | By Ellen Johnson | Macroaxis Story |
Why analysts lower Pfizer buy or sell consensus to Hold? Pfizer Average Equity is expected to decrease significantly based on the last few years of reporting. The past year's Average Equity was at 61.66 Billion. The current year Free Cash Flow is expected to grow to about 11.2 B, whereas Average Assets are expected to decline to about 158.5 B. Next fiscal quarter end is expected on the 30th of June 2020. The stock experiences sell-off trend. Whilst many millenniums are getting more into robots and drones space, it makes sense to digest Pfizer Inc. We will cover the possibilities of making Pfizer into a steady grower in July. Analysts have now less confidence in Pfizer as compared to a month ago. The current buy or sell recommendation of 10 analysts is Hold. What is Pfizer chance of financial distress for July 2020? We were able to analyze and collect data for thirty-eight available financial ratios for Pfizer Inc, which can be compared to its competitors. To make sure the equity is not overpriced, please check all Pfizer Inc financials, including its cash and equivalents, earnings per share, and the relationship between the revenue and current ratio . Given that Pfizer Inc has a price to earning of 13.11 X, we recommend you to check out Pfizer Inc recent market performance to make sure the company can sustain itself down the road. Use Pfizer to protect your portfolios against small markets fluctuations. The stock experiences a somewhat bearish sentiment, but market may correct it shortly. Check odds of Pfizer to be traded at $31.22 in 30 days.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Pfizer has performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.6709, which implies possible diversification benefits within a given portfolio. Let's try to break down what Pfizer's beta means in this case. As returns on the market increase, Pfizer returns are expected to increase less than the market. However, during the bear market, the loss on holding Pfizer will be expected to be smaller as well. Although it is extremely important to respect Pfizer Inc current trending patterns, it is better to be realistic regarding the information on equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing Pfizer Inc technical indicators you can presently evaluate if the expected return of 0.047% will be sustainable into the future. Pfizer Inc right now holds a risk of 2.25%. Please check Pfizer Inc total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power to decide if Pfizer Inc will be following its historical price patterns. The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0, demonstrating that Pfizer Inc may be unable to create cash to meet all of its financial commitments. Pfizer Inc has a current ratio of 1.44, which is typical for the industry and considered as normal. Pfizer is UNDERVALUED at 37.22 per share with modest projections ahead. What is the right price you would pay to acquire a share of Pfizer? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
What is happening with Pfizer Inc this year
Annual and quarterly reports issued by Pfizer Inc are formal financial statements that are published yearly and quarterly and sent to Pfizer stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Pfizer often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Pfizer Gross Profit
Pfizer Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pfizer previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pfizer Gross Profit growth over the last 10 years. Please check Pfizer's gross profit and other fundamental indicators for more details.
What is driving Pfizer Investor Appetite?
Average experts consensus on the organization has changed. Analysts have now less confidence in the company as compared to a month ago. The current buy or sell recommendation of 10 analysts is Hold. Pfizer has 47.96 B in debt with debt to equity (D/E) ratio of 80.0, demonstrating that the firm may be unable to create cash to meet all of its financial commitments. This firm has a current ratio of 1.44, which is typical for the industry and considered as normal. The entity reported last year revenue of 53.04 B. Total Income to common stockholders was 16.21 B with profit before taxes, overhead, and interest of 42.52 B. Pfizer Net Income Per Employee is rather stable at the moment. Also, Pfizer Average Assets is decreasing over the last 8 years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Pfizer Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.